Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell-Culture Influenza Vaccine (2007/2008) in Adults and Elderly
NCT00511914Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of TIVc in influenza (2 arms), sponsored by Novartis. Primary endpoints: Geometric Mean Titers at Day 22, Geometric Mean Ratio at Day 22 and 2 more. Started Jul 2007; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00511914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511914.